In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization

Kristen F. Soodak, Celeste R. Brennecka, Brent Vernon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA575 and PEGDA 700), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA575-QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA700-QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA575-QT gels achieved a maximum mass increase of 72% due to water uptake, while PEGDA700-QT gels doubled their initial mass (100% increase) by 165 days. Compression tests showed that PEGDA700-QT gels hydrolyzed more quickly than PEGDA575-QT gels. Cytotoxicity assays showed that in general, PEGDA575-QT negatively affected cell growth, while PEGDA700-QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA700-QT gels, but PEGDA575-QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA700-QT gels swell more and degrade faster than PEGDA575-QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 101B: 1477-1488, 2013.

Original languageEnglish (US)
Pages (from-to)1477-1488
Number of pages12
JournalJournal of Biomedical Materials Research - Part B Applied Biomaterials
Volume101
Issue number8
DOIs
StatePublished - 2013

Fingerprint

Intracranial Aneurysm
Polymers
Gels
Pharmaceutical Preparations
In Vitro Techniques
poly(ethylene glycol) diacrylate-pentaerythritol tetrakis(3-mercaptopropionate)
Drug Liberation
Cytotoxicity
Proteins
Aneurysm
Cell growth
Muramidase

Keywords

  • cerebral aneurysm
  • degradation
  • embolization
  • in vitro characteristics
  • model drug release

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization. / Soodak, Kristen F.; Brennecka, Celeste R.; Vernon, Brent.

In: Journal of Biomedical Materials Research - Part B Applied Biomaterials, Vol. 101, No. 8, 2013, p. 1477-1488.

Research output: Contribution to journalArticle

@article{ee68c9981b3847eab07aa56d6322d048,
title = "In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization",
abstract = "A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA575 and PEGDA 700), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA575-QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA700-QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA575-QT gels achieved a maximum mass increase of 72{\%} due to water uptake, while PEGDA700-QT gels doubled their initial mass (100{\%} increase) by 165 days. Compression tests showed that PEGDA700-QT gels hydrolyzed more quickly than PEGDA575-QT gels. Cytotoxicity assays showed that in general, PEGDA575-QT negatively affected cell growth, while PEGDA700-QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA700-QT gels, but PEGDA575-QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA700-QT gels swell more and degrade faster than PEGDA575-QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment. {\circledC} 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 101B: 1477-1488, 2013.",
keywords = "cerebral aneurysm, degradation, embolization, in vitro characteristics, model drug release",
author = "Soodak, {Kristen F.} and Brennecka, {Celeste R.} and Brent Vernon",
year = "2013",
doi = "10.1002/jbm.b.32969",
language = "English (US)",
volume = "101",
pages = "1477--1488",
journal = "Journal of Biomedical Materials Research - Part B Applied Biomaterials",
issn = "0021-9304",
publisher = "Heterocorporation",
number = "8",

}

TY - JOUR

T1 - In vitro characteristics of a gelling PEGDA-QT polymer system with model drug release for cerebral aneurysm embolization

AU - Soodak, Kristen F.

AU - Brennecka, Celeste R.

AU - Vernon, Brent

PY - 2013

Y1 - 2013

N2 - A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA575 and PEGDA 700), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA575-QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA700-QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA575-QT gels achieved a maximum mass increase of 72% due to water uptake, while PEGDA700-QT gels doubled their initial mass (100% increase) by 165 days. Compression tests showed that PEGDA700-QT gels hydrolyzed more quickly than PEGDA575-QT gels. Cytotoxicity assays showed that in general, PEGDA575-QT negatively affected cell growth, while PEGDA700-QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA700-QT gels, but PEGDA575-QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA700-QT gels swell more and degrade faster than PEGDA575-QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 101B: 1477-1488, 2013.

AB - A liquid-to-solid gelling polymer system, such as the poly(ethylene glycol) diacrylate-pentaerythritol tetrakis (3-mercaptopropionate) (PEGDA-QT) system, can fill cerebral aneurysms more completely than current embolization materials, reducing the likelihood of aneurysm recurrence. PEGDA-QT gels were formulated using PEGDA of different molecular weights (PEGDA575 and PEGDA 700), and their characteristics were examined in vitro. Experiments examined gel time, mass change, crosslink integrity, cytotoxicity, and protein release capabilities. In general, PEGDA575-QT gels were more hydrophobic, requiring an initiating solution with a higher pH (pH 9.5) to achieve a gel time comparable to PEGDA700-QT gels, which used an initiating solution at pH 9.19. The mass change and crosslink integrity of gels were analyzed over time after gels were submerged in 150 mM phosphate buffered saline. After 380 days, PEGDA575-QT gels achieved a maximum mass increase of 72% due to water uptake, while PEGDA700-QT gels doubled their initial mass (100% increase) by 165 days. Compression tests showed that PEGDA700-QT gels hydrolyzed more quickly than PEGDA575-QT gels. Cytotoxicity assays showed that in general, PEGDA575-QT negatively affected cell growth, while PEGDA700-QT gels promoted cell viability. Sustained, controlled release of lysozyme, a 14.3 kDa protein, was achieved over an 8-week period when loaded into PEGDA700-QT gels, but PEGDA575-QT gels did not show sustained release. These studies show that although they are similar in composition, these PEGDA-QT gel formulations behave considerably differently. Although PEGDA700-QT gels swell more and degrade faster than PEGDA575-QT gels, their cytocompatibility and protein release characteristics may prove to be more beneficial for in vivo aneurysm treatment. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 101B: 1477-1488, 2013.

KW - cerebral aneurysm

KW - degradation

KW - embolization

KW - in vitro characteristics

KW - model drug release

UR - http://www.scopus.com/inward/record.url?scp=84886542127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886542127&partnerID=8YFLogxK

U2 - 10.1002/jbm.b.32969

DO - 10.1002/jbm.b.32969

M3 - Article

VL - 101

SP - 1477

EP - 1488

JO - Journal of Biomedical Materials Research - Part B Applied Biomaterials

JF - Journal of Biomedical Materials Research - Part B Applied Biomaterials

SN - 0021-9304

IS - 8

ER -